OAM
QNCX icon

Oxford Asset Management’s Quince Therapeutics QNCX Stock Holding History

Oxford Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-35
Closed -$398K – 1044
2019
Q4 		$398K Sell
35
-98
-74% -$591K 0.01% 1334
2019
Q3 		$664K Sell
133
-132
-50% -$812K 0.02% 1140
2019
Q2 		$2.25M Buy
+265
New +$1.58M 0.05% 592

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Oxford Asset Management's QNCX Position: Q1 2020 in Review

Oxford Asset Management sold out of Quince Therapeutics (QNCX) in Q1 2020, closing a stake of 35 shares — an estimated $398K sold.

Oxford Asset Management first reported a position in QNCX in Q2 2019 and held it in 3 quarters. The position peaked at $2.25M in Q2 2019. 63 funds tracked by Wall St. Rank hold QNCX as of Q1 2020.

  • Oxford Asset Management reported no remaining Quince Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 35 Quince Therapeutics shares in Q1 2020, an estimated $398K.
  • Oxford Asset Management first reported a position in Quince Therapeutics in Q2 2019 and held it in 3 quarters.
  • Oxford Asset Management's Quince Therapeutics position peaked at $2.25M in Q2 2019.
  • 63 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.